103 related articles for article (PubMed ID: 12269976)
1. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
2. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of proton pump inhibitors on dexamethasone plus pylorus ligation induced ulcer model in rats.
Thippeswamy AH; Sajjan M; Palkar MB; Koti BC; Viswanathaswamy AH
Indian J Pharm Sci; 2010 May; 72(3):367-71. PubMed ID: 21188049
[TBL] [Abstract][Full Text] [Related]
4. Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study.
Fukui R; Noda S; Ikeda Y; Sawayama Y; Terada T; Nakagawa Y; Morita SY
Clin Pharmacol Ther; 2024 May; 115(5):1141-1151. PubMed ID: 38258325
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.
Park S; Hyun YJ; Kim YR; Lee JH; Ryu S; Kim JM; Oh WY; Na HS; Lee JG; Seo DW; Hwang IY; Park Z; Jang IJ; Oh J; Choi SE
J Korean Med Sci; 2017 May; 32(5):729-736. PubMed ID: 28378544
[TBL] [Abstract][Full Text] [Related]
6. [Galactorrhea induced by lansoprazole].
Izquierdo Prieto OM; Moreno Alía E; Rosillo González A
Aten Primaria; 2004 Oct; 34(6):325-6. PubMed ID: 15491529
[No Abstract] [Full Text] [Related]
7. Proton pump inhibitors: Weighing the benefits and risks across various health conditions.
Sizgoric L; Likic R
Br J Clin Pharmacol; 2024 Feb; 90(2):388-391. PubMed ID: 38013514
[No Abstract] [Full Text] [Related]
8. Rabeprazole destroyed gastric epithelial barrier function through FOXF1/STAT3-mediated ZO-1 expression.
Yang F; Li L; Zhou Y; Pan W; Liang X; Huang L; Huang J; Cheng Y; Geng L; Xu W; Gong S
Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):516-526. PubMed ID: 36897043
[TBL] [Abstract][Full Text] [Related]
9. Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition.
Ghosh N; Kesh K; Singh PK; Sharma U; Chupikova I; Ramakrishnan S; Roy S
Br J Pharmacol; 2023 Jun; 180(12):1582-1596. PubMed ID: 36585367
[TBL] [Abstract][Full Text] [Related]
10. Greenness-sustainability metrics for assessment smart-chemometric spectrophotometric strategy for evaluation of the combination of six gastric proton-pump inhibitors with two selected impurities.
Amin KFM
MethodsX; 2024 Jun; 12():102670. PubMed ID: 38577411
[TBL] [Abstract][Full Text] [Related]
11. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Román M; Ochoa D; Sánchez-Rojas SD; Talegón M; Prieto-Pérez R; Rivas Â; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2014; 15(15):1893-901. PubMed ID: 25495411
[TBL] [Abstract][Full Text] [Related]
13. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms.
Li S; Xie L; Yang L; Jiang L; Yang Y; Zhi H; Liu X; Yang H; Liu L
Pharm Res; 2023 Jul; 40(7):1735-1750. PubMed ID: 37226024
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of
Zhang Z; Liu F; Ai F; Chen X; Liu R; Zhang C; Fang N; Fu T; Wang X; Tang A
Front Pharmacol; 2023; 14():1143969. PubMed ID: 37214450
[No Abstract] [Full Text] [Related]
16. Helicobacter pylori infection.
Malfertheiner P; Camargo MC; El-Omar E; Liou JM; Peek R; Schulz C; Smith SI; Suerbaum S
Nat Rev Dis Primers; 2023 Apr; 9(1):19. PubMed ID: 37081005
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies.
Hidaka Y; Imai T; Inaba T; Kagawa T; Omae K; Tanaka S
PLoS One; 2021; 16(12):e0261703. PubMed ID: 34941937
[TBL] [Abstract][Full Text] [Related]
18. Different dose of new generation proton pump inhibitors for the treatment of
Gao W; Zhang X; Yin Y; Yu S; Wang L
Int J Immunopathol Pharmacol; 2021; 35():20587384211030397. PubMed ID: 34250840
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
